ReViral Inc.

https://www.reviral.co.uk

ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors, strong drug-like characteristics and good pharmacokinetic properties offering versatility in the route of administration. The lead candidate, sisunatovir, completed a Phase 2a trial in adult volunteers, showing high potency and was well tolerated. The company also has an RSV replication programme at an earlier stage of development and plans to expand its pipeline. In July 2018, ReViral completed a $55 million Series B funding round from a group of leading venture capital investors jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed and Brace Pharma Capital also participated in the fundraising. *

	Start	2019-10-22 existent
	Group	ReViral (Group)
	Industry	virostatic agent
	Industry 2	sisunatovir (RV521)
	Person	Littler, Edward (Eddy) (ReViral 201906– COO before since 201610– CEO before Domainex + Medivir)
	Person 2	Wisniewski, Raphaël (Andera Partners 202110 formerly LCF Rothschild at Edmond de Rothschild Investment Partners)

	Region	Stevenage, Hertfordshire
	Country	United Kingdom (GB)
	Street	2530 Meridian Parkway 2nd Floor
	City	27713 Durham, NC
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: ReViral Ltd.. (10/21/19). "Press Release: ReViral Announces Appointment of Alan Musso as Chief Financial Officer". London.

		Record changed: 2023-07-10